Scalper1 News
Big-cap biotech Biogen Idec (BIIB) said Tuesday that it’s moving its drug candidate for Alzheimer’s disease into late-stage testing after promising early-stage results, sending the stock up 6% in heavy trading in the stock market today. At the Deutsche Bank BioFEST conference in Boston, Biogen executives said that results from a 194-patient phase one trial for BIIB-037, which it is jointly developing with Japan’s Eisai, were good enough to push Scalper1 News
Scalper1 News